Generic drugmakers start shipping copies of Takeda’s ADHD drug Vyvanse
Aug 31 (Reuters) - Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's (4502.T) drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
Other Articles in this Edition
ADHD: A risk factor for serious mental health issues, research finds
Generic drugmakers start shipping copies of Takeda’s ADHD drug Vyvanse
ADHD drug shortage stresses families during back-to-school season
Counterfeit Pills Fuel Rising Number of Fatal Drug Overdoses
Study Explores Effects of Sleep Robot Intervention on Patients With ADHD and Insomnia
Family says Catholic medical clinic denied transgender girl care
Research: Gender affects when someone is diagnosed with ADHD
EU regulator recommends pregnant women not use epilepsy drug topiramate
Seeing the invisible: Learning to accommodate neurodivergence at work